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Abstract
Rationale: Aspects of schizophrenia, including deficits in sensorimotor
gating, have been linked to glutamate dysfunction and/or oxidative stress in
the prefrontal cortex. System xc−, a cystine- glutamate antiporter, is a poorly
understood mechanism that contributes to both cellular antioxidant capacity
and glutamate homeostasis.
Objectives: Our goal was to determine whether increased system xc− activity
within the prefrontal cortex would normalize a rodent measure of
sensorimotor gating.
Methods: In situ hybridization was used to map mRNA expression of xCT, the
active subunit of system xc−, in the prefrontal cortex. Prepulse inhibition was
used to measure sensorimotor gating; deficits in prepulse inhibition were
produced using phencyclidine (0.3–3 mg/kg, sc). N-acetylcysteine (10–100
μM) and the system xc− inhibitor (S)-4-carboxyphenylglycine (CPG, 0.5 μM)
were used to increase and decrease system xc− activity, respectively. The
uptake of 14C-cystine into tissue punches obtained from the prefrontal cortex
was used to assay system xc− activity.
Results: The expression of xCT mRNA in the prefrontal cortex was most
prominent in a lateral band spanning primarily the prelimbic cortex. Although
phencyclidine did not alter the uptake of 14C-cystine in prefrontal cortical
tissue punches, intra-prefrontal cortical infusion of N-acetylcysteine (10–100
μM) significantly reduced phencyclidine- (1.5 mg/kg, sc) induced deficits in
prepulse inhibition. N-acetylcysteine was without effect when co-infused with
CPG (0.5 μM), indicating an involvement of system xc−.
Conclusions: These results indicate that phencyclidine disrupts sensorimotor
gating through system xc− independent mechanisms, but that increasing
cystine-glutamate exchange in the prefrontal cortex is sufficient to reduce
behavioral deficits produced by phencyclidine.
Keywords: schizophrenia, prefrontal cortex, prepulse inhibition,
phencyclidine, sensorimotor gating, glutamate, system x c−, nonvesicular,
cystine-glutamate antiporter

Introduction
Abnormal activity within the prefrontal cortex has been linked to
schizophrenia and may contribute to aspects of the disease that are
only marginally responsive to existing antipsychotic medications
(Berman et al. 1986; Garey et al. 1998; Glantz and Lewis 2000;
Lieberman et al. 2005; Rajkowska et al. 1998). Dysregulation of
excitatory signaling has been widely linked to deficits in prefrontal
cortical activity observed in schizophrenia (Bunney and Bunney 2000;
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Javitt et al. 2011; Moghaddam and Javitt 2012), although the nature
of the potential pathological changes are not clear. Reduced,
increased, or de-synchronized excitatory activity in the prefrontal
cortex has been proposed to occur in schizophrenia (Franzen and
Ingvar 1975; Ingvar and Franzen 1974; Jackson et al. 2004;
Moghaddam and Adams 1998; Potkin et al. 2009). Identifying the
cellular basis of prefrontal deficits in more detail, especially as it
relates to excitatory signaling, will advance our understanding of the
neurobiology of schizophrenia and possibly reveal novel therapeutic
targets.
The equivocal nature of excitatory signaling in relation to
abnormal prefrontal cortical activity may stem from critical gaps in our
understanding of glutamate. Although often described as the primary
excitatory neurotransmitter in the brain (Coyle and Puttfarcken 1993;
Marino et al. 2001), we are only now unmasking how the many
components of this complex network of receptors, membraneexpressed enzymes, transporters, and release mechanisms function in
an integrated manner to regulate the neurotransmitter actions of this
amino acid. Extant data indicate the existence of multiple glutamate
release mechanisms by astrocytes (Araque et al. 2000; Bezzi et al.
1998; Parpura et al. 1994; Pasti et al. 2001; Ye et al. 2003) that may
independently maintain glutamate concentrations in distinct
compartments (e.g., synaptic and extrasynaptic; Bridges et al. 2012).
If this is the case, a hypo- and hyper-glutamatergic state may exist in
these separate compartments.
System xc− is an example of a poorly understood regulator of
glutamate homeostasis that may exert profound control over multiple
aspects of synaptic function (Baker et al. 2002; Moran et al. 2005;
Moussawi et al. 2009; Moussawi et al. 2011). Originally identified over
thirty years ago as a sodium-independent glutamate transporter
(Bannai and Kitamura 1980), system xc− functions as a cystineglutamate antiporter or exchanger that couples the uptake of one
molecule of extracellular cystine to the release of one molecule of
intracellular glutamate (Bannai 1986; Piani and Fontana 1994).
Nonvesicular glutamate release by system xc− regulates synaptic
activity by stimulating extrasynaptic receptors including inhibitory
group II metabotropic glutamate receptors (Baker et al. 2002; Kupchik
et al. 2011; Moran et al. 2005; Pow 2001), which is thought to then
inhibit synaptic neurotransmitter release (Battaglia et al. 1997; Moran
et al. 2005). Thus, manipulations of system xc− activity could
differentially impact levels of extracellular glutamate in extrasynaptic
and synaptic compartments. An important question to be addressed is
whether increased system xc− activity in the prefrontal cortex is
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sufficient to manipulate behaviors thought to stem from excitatory
signaling within the prefrontal cortex, especially since extant data
suggest that system xc− activity in the prefrontal cortex may be altered
in schizophrenia (Baker et al. 2008; Do et al. 2000; Raffa et al. 2011).
The purpose of the current set of studies was to determine
whether system xc− activity in the prefrontal cortex may influence
sensorimotor gating, in part because it may be altered in schizophrenia
as a result of abnormal excitatory signaling in the prefrontal cortex
(Koch and Bubser 1994; Kumari et al. 2008; Majic et al. 2011;
Swerdlow et al. 2001; Wilmsmeier et al. 2010). Sensorimotor gating
refers to the ability of the central nervous system to regulate the
capacity of sensory information to influence behavior (Braff and Geyer
1990; Graham 1975; Swerdlow et al. 1986). It is often assessed in
rodents using prepulse inhibition, which involves measuring the
inhibition of a startle response when the onset of the startle-eliciting
auditory stimuli is indicated to the subject by a preceding, relatively
mild acoustic stimulus. Attempts to reveal the neural basis of
sensorimotor gating deficits in schizophrenia often involve the use of
non-competitive NMDA receptor antagonists, such as phencyclidine, to
disrupt prepulse inhibition of an acoustic startle response (Braff et al.
1978; Geyer et al. 2001; Swerdlow et al. 2006).

Materials and Methods
Animals and Surgeries
Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing
300–400 grams were individually housed in a temperature controlled
room with a 12-h light/dark cycle with food and water ad libitum. The
housing conditions and care of the rats were in accordance with the
Animal Welfare Act, and all procedures were approved by the
Marquette University IACUC Committee. The total number of rats used
in these experiments was 172; each rat was tested only once. Rats
used in the microdialysis studies were anesthetized using pentobarbital
(50 mg/kg, IP) with atropine sulfate (1 mg/kg, IP) pretreatment to
limit tracheobronchial secretions. One pair of bilateral guide cannula
(20 gauge, 14 mm; Plastics One, Roanoke, VA) were implanted using
coordinates (+3.1 mm anterior, ±1.0 mm mediolateral to Bregma, and
−0.75 mm ventral from the surface of the skull at a 6° angle from
vertical) derived from Paxinos and Watson (Paxinos and Watson
1986). Following surgery, rats were provided acetaminophen (480
mg/L) in their drinking water for 2 days and were given at least six
days to recover prior to testing.

Psychopharmacology, Vol. 226, No. 3 (April 2013): pg. 531-540. DOI. This article is © Springer and permission has been
granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article to be
further copied/distributed or hosted elsewhere without the express permission from Springer.

4

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

In situ hybridization
Brains were rapidly removed and frozen in optimal cutting
temperature solution (OCT, Sakura, Torrance, CA) in a dry ice and
ethanol bath and then cut into 12 μm coronal sections. Standard in
vitro transcription methods were used to generate riboprobes against
xCT (Choi, Milwaukee, WI) which was subsequently diluted in
hybridization cocktail (Amresco, Solon, OH) and tRNA. Sections were
hybridized overnight at 55°C in a mixture of tRNA, formamide,
dextran, NaCl, EDTA, Denhardt’s solution and 33P-labeled riboprobe.
After hybridization, slides were rinsed in 2× SSC buffer (pH 7.0). They
were treated with RNase A in a 0.5 M sodium chloride, 10 mM Tris, 1
mM EDTA buffer for 30 min at 37 °C and then washed in the same
buffer without RNase A for 30 min at 37 °C. Slides were stringently
washed in 0.5× SSC for 30 min at 6 °C and then exposed to
autoradiographic film (3 days) and then subsequently coated with
Kodak autoradiographic emulsion NTB (Rochester, NY) and exposed for
9 days to produce silver grains. Following standard autoradiography
development, NTB emulsion-dipped sections were counterstained with
0.5% cresyl violet. Photodocumentation of silver grains was achieved
using dark field microscopy (Axioskop-2, Zeiss, Thornwood, NY) and
Axiovision image analysis software (Zeiss, Thornwood, NY).

[14C]Cystine Uptake
Rats were decapitated and the brains were rapidly extracted and
cut into 1 mm coronal slices using a brain matrix. Tissue punches
(1.25 mm diameter, Stoelting, Wood Dale, IL) were collected from the
medial prefrontal cortex and incubated at 37°C for approximately 30
minutes on a nylon bolting cloth platform, submerged beneath 2 mm
of standard buffer (Lobner and Lipton 1993); the standard buffer
contained 124 mM NaCl, 3.0 mM KCl, 1.4 mM KH2PO4, 1.3 mM MgSO4,
26 mM NaHCO3, 2.4 mM CaCl2, and 4 mM glucose, equilibrated with
95% O2, 5% CO2; pH was 7.4. After a 30 min wash, the tissue was
incubated for 10 minutes in standard buffer containing phencyclidine
(0 or 3 μM) or the system xc− inhibitor (S)-4-carboxyphenylglycine
(CPG; 0 or 1 mM). 14C-cystine (0.03 μ Ci/ml; PerkinElmer, Boston, MA)
and DL-threo-β-Benzyloxyaspartic acid (10 μM; to prevent the uptake
of cystine via XAG) was then added to the incubation buffer for ten
minutes. Next, the tissue punches were washed 4 times in ice cold
standard buffer and dissolved in 250 μl of 1% sodium dodecyl sulfate
(SDS). One aliquot (100 μl) was used to measure 14C-cystine uptake
by scintillation counting; a second aliquot (100 μl) was used to assess
protein content by the BCA method. Cystine uptake (CPM/μg protein)
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was normalized to the vehicle group run concurrently (i.e., in the same
plate).

In Vivo Drug Treatments
Phencyclidine (0–3 mg/kg; NIDA Drug Supply Program,
Research Triangle, NC) was dissolved in isotonic saline. Nacetylcysteine (0–100 μM, Sigma Chemical Co., St Louis, MO) and CPG
(0.5 μM; Tocris-Cooksin, Ellisville, MO) was dissolved in microdialysis
buffer.

Prepulse Inhibition
Rats were placed on a platform in a sound attenuating chamber
(27.62×35.56×49.53cm); Hamilton Kinder, CA) that rested on a
motion sensing plate. A matching session was conducted to determine
the magnitude of the startle response for each rat. This session
consisted of a five minute habituation period followed by 20 trials; 17
trials involved the presentation of a single auditory stimulus (pulse
stimulus; 50 dB above the 60 dB background noise, 40 ms duration)
and three trials in which a prepulse stimulus (12 dB above
background, 20 ms duration) was presented 100 ms before the pulse
stimulus. Rats were then assigned into the various treatment groups
based on the magnitude of their startle response. At least one day
later, an experimental session was conducted to assess sensorimotor
gating. On this day, rats received a 5 or 10 min habituation period
followed by 58 discrete trials; eight background trials with only
background noise, 26 trials with only the pulse stimulus (50 dB above
background), and 24 trials with the pulse stimulus being preceded by
one of three prepulse stimuli (2, 6, or 15 dB above background). The
percent of prepulse inhibition was determined as 100-(average
prepulse startle response/average startle stimulus alone)*100.

In Vivo Microdialysis
Microdialysis probes, constructed as previously described (Baker
et al. 2002). The active membrane, approximately 1 mm in total
length, began 1 mm beyond the most distal aspect of the guide
cannula to minimize the influence of tissue damaged by the guide
cannula to our measures. Dialysis buffer (5 mM glucose, 140 mM NaCl,
1.4 mM CaCl2, 1.2 mM MgCl2, and 0.15% phosphate buffer saline, pH
7.4) was pumped through the probes at a rate of 1 μl/min. Drugs were
administered as described below for each experiment. Reverse dialysis
was used for local infusions since it permits delivery of a low
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concentration of a drug (especially when considering an average
recovery rate of 7% that is typical of our probes) across time as well
as across the dorsal-ventral axis of the prefrontal cortex.

Histology
Rats included in the microdialysis studies were given an
overdose of pentobarbital (60 mg/kg, IP), and the brains were fixed by
intracardiac infusion of 0.9% saline followed by 2.5% formalin
solution. Brains were removed and stored in 2.5% formalin for at least
seven days prior to sectioning. The tissue was then blocked and
coronal sections (100 μM) were cut and stained with cresyl violet to
verify probe placements. Rats determined to have misplaced guide
cannula were excluded from all behavioral analyses.

Statistics
Primary comparisons involving only two groups (i.e., Exps 1 and
5) were analyzed using an independent-samples T-test. Primary
comparisons involving more than two groups were analyzed using
ANOVA with drug treatment (i.e., phencyclidine, N-acetylcysteine) as
between-subjects factors and prepulse intensity as a repeated
measure. The presence or absences of CPG was used as an additional
between subjects variable used in experiment 4. Significant
interactions and main effects were further analyzed using Tukey HSD
(p<0.05).

Design of experiment 1
This experiment was designed to characterize system xc− in the
prefrontal cortex. First, we used in situ hybridization to determine the
distribution of mRNA of xCT, the active subunit for system xc−. Next,
we measured 14C-cystine uptake in ex vivo tissue punches obtained
from the prefrontal cortex in the absence or presence of the system
xc− inhibitor CPG to confirm the existence of cystine-glutamate
exchange by system xc−.

Design of experiment 2
The purpose of this experiment was to select a dose of
phencyclidine for subsequent experiments. Rats received an acute
injection of phencyclidine (0–3 mg/kg, SC) ten minutes before being
placed in the startle chamber. Testing was conducted as described
above.
Psychopharmacology, Vol. 226, No. 3 (April 2013): pg. 531-540. DOI. This article is © Springer and permission has been
granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article to be
further copied/distributed or hosted elsewhere without the express permission from Springer.

7

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Design of experiment 3
This experiment was designed to determine the impact of
increased cystine-glutamate exchange on phencyclidine-induced
deficits in prepulse inhibition. To do this, we reverse dialyzed the
cysteine prodrug N-acetylcysteine (0–100 μM) directly into the
prefrontal cortex for one hour prior to and after phencyclidine (0 or 1.5
mg/kg, SC) administration. One hour after phencyclidine, the probes
were removed and rats underwent prepulse inhibition testing as
described above.

Design of experiment 4
This experiment was designed to verify that N-acetylcysteine
antagonizes phencyclidine-induced deficits in prepulse inhibition by
increasing system xc− activity in the prefrontal cortex. To do this, the
system xc− inhibitor CPG (0 or 0.5 μM), was infused into the prefrontal
cortex. Twenty minutes later, N-acetylcysteine (0 or 30 μM) was added
to the dialysis buffer such that CPG and N-acetylcysteine were coinfused until prepulse inhibition testing. One hour after CPG and Nacetylcysteine treatment began, phencyclidine was administered (0–
1.5 mg/kg, SC). One hour post phencyclidine, the probes were
removed and rats underwent prepulse inhibition testing as described
above.

Design of experiment 5
This experiment was used to determine whether phencyclidine
directly influences the rate of cystine-glutamate exchange by system
xc−. To do this, we measured the uptake of 14C-cystine uptake in
prefrontal cortical tissue punches incubated in the absence (N = 9) or
presence (N = 7) of phencyclidine (3 μM). The concentration of
phencyclidine chosen exceeds estimates of NMDA receptor affinity for
this compound by 3–15 fold (Morris et al. 2005).

Results
System xc− appears to be differentially expressed across
subregions of the prefrontal cortex. The distribution of xCT mRNA
within the prefrontal cortex reveals a particularly prominent lateral
band of xCT mRNA contained primarily in the prelimbic cortex (see
Figure 1). The uptake of 14C-cystine by tissue punches obtained from
this subregion of the prefrontal cortex was significantly reduced by the
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system xc− inhibitor CPG (t(14)=12.4, p<0.001) revealing the existence
of functional cystine-glutamate exchange by system xc− in this region.

Fig. 1

Cystine-glutamate exchange by system xc− activity is present in the
prefrontal cortex. (a) A representative coronal section displaying the expression
pattern of xCT mRNA via in situ hybridization (left, dark field photomicrograph). The
right illustration, adapted from (Paxinos and Watson 1998), indicates that xCT mRNA
is primarily expressed in prelimbic region of the prefrontal cortex (PrL) with minimal
expression in the infralimbic cortex (IL). (b) The uptake of 14C-cystine by prefrontal
cortical tissue punches in the absence or presence of the system xc− inhibitor (S)-4carboxyphenylglycine (CPG). The number of subjects for each group is listed in the bar
graph. * indicates a difference from controls (t-test, p < 0.05).

Phencyclidine produced a dose-dependent impairment in
prepulse inhibition of the acoustic startle reflex (see Figure 2). An
ANOVA with drug treatment as a between subjects variable and
prepulse intensity as a repeated measure yielded a significant
interaction (F(12,102)=5.77, p<0.001). Analysis of the simple main
effects revealed a significant main effect of drug treatment at prepulse
intensities of six (F(6,57)=9.20, p<0.001) and 15 dB (F(6,57)=14.79,
p<0.001), but not two dB (F(6,57)=0.40, p=0.88). Post hoc analyses
indicated that phencyclidine produced deficits in prepulse inhibition at
doses exceeding 1 mg/kg (Tukey, p<0.05). A main effect of
phencyclidine treatment (F(6,57)=5.80, p<0.001) on startle magnitude
was obtained. Post-hoc analysis revealed that phencyclidine dosePsychopharmacology, Vol. 226, No. 3 (April 2013): pg. 531-540. DOI. This article is © Springer and permission has been
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dependently (1.25, 2.0 mg/kg) altered startle magnitude (Table 1;
Tukey, p<0.05).

Fig. 2

Phencyclidine produces a dose-dependent disruption of prepulse inhibition.
The data is expressed as the mean (+ SEM) percent inhibition of the startle response
to a loud auditory stimulus when preceded by a mile-modest, nonstartle-eliciting
auditory cue ranging between 2–15 dB. Behavior depicted was obtained from rats that
had received an acute injection of phencyclidine (PCP, 0–3 mg/kg; SC) ten minutes
prior to testing. * indicates a difference from controls receiving 0 mg/kg phencyclidine
(Tukey HSD, P<0.05).

Figure 3a depicts the impact of N-acetylcysteine infused into the
medial prefrontal cortex via reverse dialysis on phencyclidine-induced
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deficits in sensorimotor gating. An ANOVA with drug treatment as a
between subjects variable and prepulse intensity as a repeated
measure yielded a significant interaction (F(8,54)=2.26, p<0.05).
Analysis of the simple main effects revealed a significant effect of drug
at every prepulse intensity (2 dB: F(4,31)=4.12, p = 0.01; 6 dB:
F(4,31)=10.70, p<0.001; 15 dB: F(4,31)=7.15, p<0.001). Post hoc
analyses indicated that phencyclidine-induced impairment of
sensorimotor gating was attenuated by N-acetylcysteine at every
prepulse intensity (figure 4; Tukey, p<0.05). There were no significant
differences in the startle amplitude between the groups included in this
study (ANOVA: F(4,33)= 0.21, p>0.05, table 1). The subregion of the
prefrontal cortex targeted in the microdialysis studies is depicted in
Figure 3b.

Fig. 3

N-acetylcysteine infused into the prefrontal cortex antagonizes phencyclidineinduced deficits in prepulse inhibition. (a) The mean (+ SEM) prepulse inhibition
displayed by rats receiving N-acetylcysteine (NAC, 0 – 100 μM) into the prefrontal
cortex followed 1 hour later by an acute injection of phencyclidine (0 or 1.5 mg/kg,
SC). * indicates a significant difference from control rats receiving only saline (NAC
0/PCP 0; Tukey HSD, p < 0.05). + indicates a significant difference from rats receiving
only phencyclidine (NAC 0/PCP 1.25; Tukey HSD, p < 0.05). (b) The microdialysis
probes were placed primarily in the prelimbic cortex (PrL), although aspects of the
infralimbic (IL) may have been perfused as well. A representative coronal section
illustrates the placement of a microdialysis probe. The tract created extends
approximately 2 mm from the guide cannula with sampling only occurring from the
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most ventral 1 mm because this is the portion of the probe containing the dialysis
membrane.

Fig. 4

N-acetylcysteine targets system xc− to antagonize deficits in prepulse
inhibition produced by phencyclidine. The data is expressed as mean (+ SEM) prepulse
inhibition displayed by rats receiving intra-prefrontal N-acetylcysteine (30 μM) (a) in
the absence or (b) or presence of the system xc− inhibitor CPG (0.5 μM) co-infused
into the prefrontal cortex. CPG was infused alone for 20 min, N-acetylcysteine was
then added to the microdialysis buffer for 60 min prior to the injection of phencyclidine
(1.5 mg/kg, SC). (a and b) * indicates a significant difference from respective vehicle
controls (i.e., rats receiving NAC 0/PCP 0; Tukey HSD, p < 0.05). + indicates a
significant difference from respective phencyclidine controls (NAC 0/PCP 1.5; Tukey
HSD, p < 0.05).

Figure 4 demonstrates that N-acetylcysteine antagonizes
phencyclidine-induced deficits in prepulse inhibition by increasing
cystine-glutamate exchange from system xc−. An ANOVA with drug
treatments (ie, N-acetylcysteine and PCP treatment) as between
subjects variables and prepulse intensity as a repeated measure
produced a significant interaction between CPG treatment and drug
treatment (F(1,46)= 4.57, p<0.05). To further deconstruct the
interaction, we examined the simple main effect of drug treatment at
each level of the CPG variable. In the absence of CPG, an ANOVA with
drug treatment as a between subjects variable and prepulse intensity
as a repeated measure yielded a significant interaction between these
variables (F(4,42)= 3.01, p<0.05). Analysis of the simple main effects
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revealed a significant main effect of drug treatment at every prepulse
intensity (2 dB: F(2,23)= 12.41, p<0.001); 6 dB F(2,23)= 13.82,
p<0.001; 15 dB F(2,23)= 12.35, p<0.001). Post hoc analyses indicated
that N-acetylcysteine antagonized phencyclidine-induced deficits in
prepulse inhibition when tested in the absence of CPG (figure 4a;
Tukey, p<0.05). In the presence of CPG, a two-way ANOVA including
treatment (N-acetylcysteine and phencyclidine treatments) as the
between subjects variable and prepulse intensity as the repeated
measures yielded a significant main effect of treatment (F(2,24)= 10.35,
p<0.001) in the absence of a significant interaction between treatment
and prepulse intensity (F(4,48)= 1.91, p>0.05). Post hoc analyses
indicated that N-acetylcysteine failed to alter phencyclidine-induced
deficits in prepulse inhibition when tested in the presence of CPG
(Figure 4b; Tukey, p>0.05). There were no significant differences in
the startle amplitude between the groups included in this study
(F(2,23)= 1.10, p>0.05; F(2,26)= 0.49, p>0.05; table 1).
A comparison of 14C-cystine uptake by tissue punches obtained
from the prefrontal cortex did not reveal an effect of phencyclidine
(t(25)=1.21, p>0.05). The mean values (± SEM) for vehicle and
phencyclidine-treated tissue punches were 100±9.9 and 83±9.2,
respectively. These data indicate that glutamate dysfunction produced
by phencyclidine does not likely involve altered activity of system xc−
in the prefrontal cortex.

Discussion
Abnormal glutamatergic signaling particularly in cortical
structures has been linked to negative symptoms and cognitive deficits
present in schizophrenia (Bunney and Bunney 2000; Deserno et al.
2012; Goghari et al. 2010; van Veelen et al. 2010). As a result,
identifying cellular mechanisms capable of regulating glutamate
signaling may advance our understanding of the neurobiological basis
of schizophrenia and facilitate the development of pharmacotherapies.
System xc−, which exchanges extracellular cystine for intracellular
glutamate (Bannai 1986; Bridges 2011), is a poorly understood
regulator of glutamate homeostasis that may exert profound control
over multiple aspects of synaptic function (Baker et al. 2002; Moran et
al. 2005; Moussawi et al. 2009; Moussawi et al. 2011) and may be
altered in schizophrenia (Baker et al. 2008; Bridges et al. 2012). The
primary finding of the present report is that infusion of the cysteine
prodrug N-acetylcysteine into the prefrontal cortex attenuates
phencyclidine-induced deficits in sensorimotor gating and this effect is
dependent upon intact system xc− activity. Collectively, these data
illustrate the capacity of system xc− to regulate a complex behavior
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involving the prefrontal cortex. Below, we discuss the potential
relevance of this data set to our understanding and potential treatment
of schizophrenia.
In the current study, infusion of N-acetylcysteine into the
prefrontal cortex antagonized phencyclidine-induced deficits in
prepulse inhibition. The effects of N-acetylcysteine on prepulse
inhibition are likely due to increased activity of system xc− in the
prefrontal cortex, particularly within the prelimbic region of this
structure. To establish this, we first verified the existence of system
xc− in the prefrontal cortex by demonstrating the presence of mRNA
for xCT, the active subunit of system xc−, and functional cystineglutamate exchange in prefrontal cortical tissue. Next, we found that
reverse dialysis of N-acetylcysteine directly into this region
antagonized phencyclidine-induced deficits in prepulse inhibition, an
effect not observed when the system xc− inhibitor CPG was co-infused.
This finding is similar to our previous observations that Nacetylcysteine required intact system xc− activity to alter multiple
behaviors including phencyclidine-induced deficits in working memory
(Baker et al. 2008; Kau et al. 2008). Interestingly, this could stem
from either the release of glutamate or the increase in intracellular
thiols expected from increased system xc− activity (Baker et al. 2002;
Bridges et al. 2012; Shimosato et al. 1995), which is expressed on
astrocytes (Pow 2001). It is important to note that studies
demonstrate the possibility that glutathione, a thiol that is dependent
upon the transport of cystine for de novo synthesis, is capable of
functioning as a signaling molecule (Janaky et al. 1999; Ogita et al.
1995), and has been shown to influence excitatory signaling (Baker et
al. 2002; Moran et al. 2005). In either case, the data are consistent
with the conclusion that astrocytes may be key in regulating the
activity of the prefrontal cortex in a manner that alters complex
behaviors. Interestingly, activation of astrocytes has recently been
shown to synchronize the firing large numbers of neurons through a
glutamate-dependent manner (Angulo et al. 2004; Poskanzer and
Yuste 2011). Thus, an important area of future research is the degree
to which system xc− may be involved in these phenomena, especially
since the origin of the glutamate may be nonvesicular (Angulo et al.
2004).
The present data may also have implications for our
understanding and treatment of schizophrenia. Phencyclidine-induced
deficits in prepulse inhibition has been used to study the neural basis
of sensorimotor gating deficits observed in schizophrenia as well and
to screen putative therapeutics that may exert antipsychotic effects
(Geyer et al. 2001; Swerdlow et al. 2008). However, the constructive
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validity of the phencyclidine model is questionable given that there are
likely to be critical distinctions between the basis of abnormal
behaviors produced by acute administration of phencyclidine and a
chronic illness such as schizophrenia. In addition, the predictive
validity of this model may also be questioned given that a number of
currently used antipsychotics fail to alter phencyclidine-induced deficits
in numerous behaviors, including prepulse inhibition. To this latter
point, however, the inability of most currently used antipsychotics to
significantly improve prepulse inhibition deficits produced by
phencyclidine may parallel the poor efficacy of these medications in
treating numerous symptoms associated with schizophrenia,
particularly those thought to involve, at least in part, the prefrontal
cortex such as sensorimotor gating and cognitive deficits (Japha and
Koch 1999; Kumari et al. 2008; Swerdlow et al. 2001). In support,
clozapine, which appears unique from other antipsychotics in that it
significantly reduces sensorimotor gating and cognitive deficits in
schizophrenia (Oranje et al. 2002), also has been shown to attenuate
phencyclidine-induced deficits in prepulse inhibition (Bakshi et al.
1994; Geyer et al. 2001; Li et al. 2011), but see (Cilia et al. 2007;
Schwabe et al. 2005).
An important question is the possibility that altered system xc−
function may be evident in schizophrenia, and, if so, whether any
potential disruption might impact the therapeutic utility of this target.
In the current study, we did not find evidence that the
psychotomimetic phencyclidine disrupted system xc− activity, although,
as discussed above, there likely are key distinctions between abnormal
behaviors produced by schizophrenia and acute phencyclidine
administration. Further, we cannot rule out the possibility that
phencyclidine alters system xc− activity under certain conditions (e.g.,
in vivo) or in a tissue-specific manner (e.g. cell type or brain region).
Regardless, in schizophrenia, glutathione levels in the dorsolateral
prefrontal cortex are significantly reduced (Do et al. 2000), which may
indicate reduced system xc−. The reason for this is that intracellular
cystine availability is thought to be the rate-limiting step in the
synthesis of this key antioxidant (Kranich et al. 1998; Sagara et al.
1993). Perhaps as a result of the decrease in glutathione, the protein
levels of xCT, the active subunit for system xc−, is significantly
increased in the dorsolateral prefrontal cortex in post-mortem tissue
obtained from individuals afflicted with schizophrenia relative to
controls (Baker et al. 2008). In support, decreased glutathione levels
has been shown to be sufficient to up-regulate system xc− (Seib et al.
2011). At the very least, these studies indicate that stimulation of
system xc− is a potential therapeutic target for schizophrenia, which
has been verified in a clinical trial (Berk et al. 2008).
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Because system xc− is at the interface between oxidative stress
and excitatory signaling, it is unclear how N-acetylcysteine reduces
behavioral and neurochemical measures in rodents that may be
relevant for schizophrenia (Baker et al. 2008; Chen et al. 2010; das
Neves Duarte et al. 2012) or the actual symptoms of the disease in
man (Berk et al. 2008; Berk et al. 2011). Specifically, system xc−
couples the uptake of extracellular cystine to the release of
intracellular glutamate (Baker et al. 2002; Bannai 1984; Bridges 2011;
Cho and Bannai 1990). Evidence implicating the glutamate component
of cystine-glutamate exchange include observations that system xc−
regulates multiple aspects of synaptic activity including extracellular
glutamate levels, activation levels of glutamate receptors, and synaptic
plasticity (Baker et al. 2002; Kupchik et al. 2011; Moran et al. 2005;
Moussawi et al. 2009; Moussawi et al. 2011). In addition, astrocytes
have been shown to synchronize the activity of large numbers of
neurons through a glutamate-dependent mechanism (Angulo et al.
2004; Poskanzer and Yuste 2011). The potential significance of the
latter point is evident from estimates that human cortical astrocytes
may contact millions of neurons (Oberheim et al. 2006). Thus,
increased glutamate release from system xc− may reverse several
cellular events linked to schizophrenia ranging from NMDA receptor
hypofunction to desynchronized firing of pyramidal neurons in the
cortex.
Evidence implicating the cystine-component of cystineglutamate exchange in the therapeutic effects of N-acetylcysteine
stems largely from observations that 1) schizophrenia is associated
with an imbalance in levels of antioxidants such as glutathione, the
synthesis of which is at least partially dependent on system xc− as
described above, and reactive oxygen species, or 2) depletion of
glutathione in rodents recreates aspects of schizophrenia (Cabungcal
et al. 2007; Gysin et al. 2011; Kulak et al. 2012; Steullet et al. 2006).
In support, a decrease in glutathione inversely correlates with the
severity of negative symptoms (Matsuzawa et al. 2008). Surprisingly,
however, N-acetylcysteine has been shown to restore numerous
interesting neurochemical abnormalities in glutathione-deficient mice
without restoring glutathione levels (das Neves Duarte et al. 2012).
Interestingly, the cystine and glutamate components of system
xc− may converge on key cellular events thought to underlie aspects of
schizophrenia, as demonstrated by the observation that depletion of
glutathione is sufficient to produce NMDA receptor hypoactivity
(Steullet et al. 2006). Collectively, these studies indicate that the
study of system xc− may have profound impact on the integration of
important components of neurophysiology such as excitatory signaling
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and oxidative stress that are often studied in isolation as well as our
ability to understand and treat debilitating CNS disease states such as
schizophrenia.
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